Replies to post #3329 on Insmed Inc (INSM)

[Do DD]

Another interesting note from the R&R CC was that the EMEA MAA for Primary IGFD was accepted in august and that a normal review cycle was expected with MA in 2007.

E.

[Christiaan F]

During CC Young says:

We continued our label expansion studies for IPLEX and now we have ongoing clinical studies where we are evaluating the
value of IPLEX in several disease areas, such as severe insulin resistance, myotonic muscular dystrophy, AIDS [unintelligible]
dystrophy and we're about to initiate a new clinical study in children with Newman's Syndrome.
Positive data from our severe insular resistance study and our pivotal IGFD studies were presented at several [unintelligible] of the Congress this last quarter and we hope to present top-line data from these new studies in the first half of 2007.
(page 2)

In Q&A part:

The timing for the next data either from severe resistant myotonic muscular dystrophy, AIDS [like] dystrophy, when can we expect to see the next data?
Phil Young - Insmed Incorporated - Chief Business Officer
We expect to see it in early '07 for everything you just mentioned.
http://preview.tinyurl.com/y2hm6x

There's NO mention of PhII results. PY is expecting DATA on all studies somewhere during H1-2007.

CF